Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03723655 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
NCT03723655: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT03723655 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 314 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (136% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03723655, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
Study Summary
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
Interventions
- DRUG mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 2 |
What the finished NCT03723655 record still lists
NCT03723655 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (136% higher).
The record links to 0 conditions, and to 1 intervention - of which mavacamten is the first listed.
NCT03723655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03723655 about?
NCT03723655 is a clinical study titled "A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM". Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Appr...
What is the current status of trial NCT03723655?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2018-09-27. Estimated completion is 2026-01-16.
What interventions are being tested in trial NCT03723655?
The interventions under investigation include: mavacamten (DRUG).
Who is sponsoring clinical trial NCT03723655?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03723655's enrollment target sits among peer trials
314 159th of 2000 higher than 1,840 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI